<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34556813</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5594</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>42</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncogene</Title>
          <ISOAbbreviation>Oncogene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.</ArticleTitle>
        <Pagination>
          <StartPage>6059</StartPage>
          <EndPage>6070</EndPage>
          <MedlinePgn>6059-6070</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41388-021-02010-1</ELocationID>
        <Abstract>
          <AbstractText>Glioblastoma (GBM) is the most common and malignant type of intracranial tumors with poor prognosis. Accumulating evidence suggests that phenotypic alterations of infiltrating myeloid cells in the tumor microenvironment are important for GBM progression. Conventional tumor immunotherapy commonly targets T-cells, while innate immunity as a therapeutic target is an emerging field. Targeting infiltrating myeloid cells that induce immune suppression in the TME provides a novel direction to improve the prognosis of patients with GBM. The factors released by tumor cells recruit myeloid cells into tumor bed and reprogram infiltrating myeloid cells into immunostimulatory/immunosuppressive phenotypes. Reciprocally, infiltrating myeloid cells, especially microglia/macrophages, regulate GBM progression and affect therapeutic efficacy. Herein, we revisited biological characteristics and functions of infiltrating myeloid cells and discussed the recent advances in immunotherapies targeting infiltrating myeloid cells in GBM. With an evolving understanding of the complex interactions between infiltrating myeloid cells and tumor cells in the tumor microenvironment, we will expand novel immunotherapeutic regimens targeting infiltrating myeloid cells in GBM treatment and improve the outcomes of GBM patients.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ye</LastName>
            <ForeName>Zengpanpan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ai</LastName>
            <ForeName>Xiaolin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Linjie</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-3372-2873</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fei</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0003-4437-3186</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital; School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan, China. 917597029@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-2429-5918</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, P. R. China. wangping_886@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shengtao</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8322-5536</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, P. R. China. taotaovip2005@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Oncogene</MedlineTA>
        <NlmUniqueID>8711562</NlmUniqueID>
        <ISSNLinking>0950-9232</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>57</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34556813</ArticleId>
        <ArticleId IdType="doi">10.1038/s41388-021-02010-1</ArticleId>
        <ArticleId IdType="pii">10.1038/s41388-021-02010-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30060998</ArticleId>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30990-5</ArticleId>
            <ArticleId IdType="pmc">30060998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70:299–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32478924</ArticleId>
            <ArticleId IdType="doi">10.3322/caac.21613</ArticleId>
            <ArticleId IdType="pmc">32478924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29260225</ArticleId>
            <ArticleId IdType="pmc">5820703</ArticleId>
            <ArticleId IdType="doi">10.1001/jama.2017.18718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. 2019;25:4202–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30804019</ArticleId>
            <ArticleId IdType="pmc">6635001</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181:1643–60 e1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32470396</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2020.05.007</ArticleId>
            <ArticleId IdType="pmc">32470396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell. 2020;181:1626–42 e1620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32470397</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.055</ArticleId>
            <ArticleId IdType="pmc">32470397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife 2020;9:e52176.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Yu G, Chu H, Wang X, Xiong L, Cai G, et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol Cell. 2018;71:201–15 e207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30029001</ArticleId>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.06.023</ArticleId>
            <ArticleId IdType="pmc">30029001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res. 2019;25:3643–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30824583</ArticleId>
            <ArticleId IdType="pmc">6571046</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon CC, Sarkar S, Yong VW, Kelly JJP. Glioblastoma-associated microglia and macrophages: Targets for therapies to improve prognosis. Brain. 2017;140:1548–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28334886</ArticleId>
            <ArticleId IdType="doi">10.1093/brain/aww355</ArticleId>
            <ArticleId IdType="pmc">28334886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18:225–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29151590</ArticleId>
            <ArticleId IdType="doi">10.1038/nri.2017.125</ArticleId>
            <ArticleId IdType="pmc">29151590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity. 2016;44:439–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26982352</ArticleId>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.02.024</ArticleId>
            <ArticleId IdType="pmc">26982352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18026097</ArticleId>
            <ArticleId IdType="doi">10.1038/nn2014</ArticleId>
            <ArticleId IdType="pmc">18026097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15831717</ArticleId>
            <ArticleId IdType="doi">10.1126/science.1110647</ArticleId>
            <ArticleId IdType="pmc">15831717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27459405</ArticleId>
            <ArticleId IdType="doi">10.1038/nn.4338</ArticleId>
            <ArticleId IdType="pmc">27459405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kees T, Lohr J, Noack J, Mora R, Gdynia G, Todt G, et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. Neuro Oncol. 2012;14:64–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22015597</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nor182</ArticleId>
            <ArticleId IdType="pmc">22015597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16520032</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2006.01.003</ArticleId>
            <ArticleId IdType="pmc">16520032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33239064</ArticleId>
            <ArticleId IdType="pmc">7689983</ArticleId>
            <ArticleId IdType="doi">10.1186/s40035-020-00221-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodama L, Gan L. Do microglial sex differences contribute to sex differences in neurodegenerative diseases? Trends Mol Med. 2019;25:741–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31171460</ArticleId>
            <ArticleId IdType="doi">10.1016/j.molmed.2019.05.001</ArticleId>
            <ArticleId IdType="pmc">31171460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thion MS, Low D, Silvin A, Chen J, Grisel P, Schulte-Schrepping J, et al. Microbiome influences prenatal and adult microglia in a sex-specific manner. Cell. 2018;172:500–16 e516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29275859</ArticleId>
            <ArticleId IdType="pmc">5786503</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2017.11.042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanamsagar R, Alter MD, Block CS, Sullivan H, Bolton JL, Bilbo SD. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia. 2017;65:1504–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28618077</ArticleId>
            <ArticleId IdType="pmc">5540146</ArticleId>
            <ArticleId IdType="doi">10.1002/glia.23176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarz JM, Sholar PW, Bilbo SD. Sex differences in microglial colonization of the developing rat brain. J Neurochem. 2012;120:948–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22182318</ArticleId>
            <ArticleId IdType="pmc">22182318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guneykaya D, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, et al. Transcriptional and translational differences of microglia from male and female brains. Cell Rep. 2018;24:2773–83 e2776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30184509</ArticleId>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.08.001</ArticleId>
            <ArticleId IdType="pmc">30184509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, et al. Sex-specific features of microglia from adult mice. Cell Rep. 2018;23:3501–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29924994</ArticleId>
            <ArticleId IdType="pmc">6024879</ArticleId>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.05.048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23096265</ArticleId>
            <ArticleId IdType="doi">10.1002/path.4133</ArticleId>
            <ArticleId IdType="pmc">23096265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roesch S, Rapp C, Dettling S, Herold-Mende C. When immune cells turn bad-tumor-associated microglia/macrophages in glioma. Int J Mol Sci. 2018;19:436.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17:170–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25580734</ArticleId>
            <ArticleId IdType="pmc">4312504</ArticleId>
            <ArticleId IdType="doi">10.1038/ncb3090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 2017;77:2266–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28235764</ArticleId>
            <ArticleId IdType="pmc">5741820</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vakilian A, Khorramdelazad H, Heidari P, Sheikh Rezaei Z, Hassanshahi G. CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017;103:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28025034</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuint.2016.12.013</ArticleId>
            <ArticleId IdType="pmc">28025034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An Z, Knobbe-Thomsen CB, Wan X, Fan QW, Reifenberger G, Weiss WA. EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma. Cancer Res. 2018;78:6785–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30401716</ArticleId>
            <ArticleId IdType="pmc">6295222</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung Y, Ahn SH, Park H, Park SH, Choi K, Choi C, et al. MCP-1 and MIP-3alpha secreted from necrotic cell-treated glioblastoma cells promote migration/infiltration of microglia. Cell Physiol Biochem. 2018;48:1332–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30048972</ArticleId>
            <ArticleId IdType="doi">10.1159/000492092</ArticleId>
            <ArticleId IdType="pmc">30048972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129:137–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30307407</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI121266</ArticleId>
            <ArticleId IdType="pmc">30307407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P, Zhao D, Li J, Liang X, Li J, Chang A, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell. 2019;35:868–84 e866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31185211</ArticleId>
            <ArticleId IdType="pmc">6561349</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.05.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SC, Hong JH, Hsueh C, Chiang CS. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab Invest. 2012;92:151–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21894147</ArticleId>
            <ArticleId IdType="doi">10.1038/labinvest.2011.128</ArticleId>
            <ArticleId IdType="pmc">21894147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sielska M, Przanowski P, Wylot B, Gabrusiewicz K, Maleszewska M, Kijewska M, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol. 2013;230:310–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23520016</ArticleId>
            <ArticleId IdType="doi">10.1002/path.4192</ArticleId>
            <ArticleId IdType="pmc">23520016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda A, Shinozaki Y, Kashiwagi K, Ohno N, Eto K, Wake H, et al. Microglia mediate non-cell-autonomous cell death of retinal ganglion cells. Glia. 2018;66:2366–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30375063</ArticleId>
            <ArticleId IdType="doi">10.1002/glia.23475</ArticleId>
            <ArticleId IdType="pmc">30375063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24316888</ArticleId>
            <ArticleId IdType="doi">10.1038/nn.3599</ArticleId>
            <ArticleId IdType="pmc">24316888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, et al. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathol. 2019;29:513–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30506802</ArticleId>
            <ArticleId IdType="pmc">6849857</ArticleId>
            <ArticleId IdType="doi">10.1111/bpa.12690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghoochani A, Schwarz MA, Yakubov E, Engelhorn T, Doerfler A, Buchfelder M, et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene. 2016;35:6246–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27157615</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2016.160</ArticleId>
            <ArticleId IdType="pmc">27157615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18:234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29262845</ArticleId>
            <ArticleId IdType="pmc">5738907</ArticleId>
            <ArticleId IdType="doi">10.1186/s13059-017-1362-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2alpha. Nat Commun. 2018;9:559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29422647</ArticleId>
            <ArticleId IdType="pmc">5805734</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-03050-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JE, Dutta B, Tse SW, Gupta N, Tan CF, Low JK, et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 2019;38:5158–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30872795</ArticleId>
            <ArticleId IdType="doi">10.1038/s41388-019-0782-x</ArticleId>
            <ArticleId IdType="pmc">30872795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian M, Wang S, Guo X, Wang J, Zhang Z, Qiu W, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-kappaB pathways. Oncogene. 2020;39:428–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31485019</ArticleId>
            <ArticleId IdType="doi">10.1038/s41388-019-0996-y</ArticleId>
            <ArticleId IdType="pmc">31485019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng X, Duan C, Pang H, Chen Q, Han B, Zha C, et al. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. EBioMedicine. 2019;41:185–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30773478</ArticleId>
            <ArticleId IdType="pmc">6442002</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ebiom.2019.01.067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K, et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci USA. 2009;106:12530–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19617536</ArticleId>
            <ArticleId IdType="pmc">2718387</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.0804273106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho da Fonseca AC, Wang H, Fan H, Chen X, Zhang I, Zhang L, et al. Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages. J Neuroimmunol. 2014;274:71–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25042352</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.06.021</ArticleId>
            <ArticleId IdType="pmc">25042352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24056773</ArticleId>
            <ArticleId IdType="pmc">3840724</ArticleId>
            <ArticleId IdType="doi">10.1038/nm.3337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Yong VW. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis. 2012;33:312–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22159219</ArticleId>
            <ArticleId IdType="doi">10.1093/carcin/bgr289</ArticleId>
            <ArticleId IdType="pmc">22159219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinton L, Masetto E, Vettore M, Solito S, Magri S, D’Andolfi M, et al. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019;7:58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30813960</ArticleId>
            <ArticleId IdType="pmc">6391795</ArticleId>
            <ArticleId IdType="doi">10.1186/s40425-019-0536-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32:42–56.e46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5599156</ArticleId>
            <ArticleId IdType="pmc">5599156</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.06.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorensen MD, Dahlrot RH, Boldt HB, Hansen S, Kristensen BW. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathol Appl Neurobiol. 2018;44:185–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28767130</ArticleId>
            <ArticleId IdType="doi">10.1111/nan.12428</ArticleId>
            <ArticleId IdType="pmc">28767130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32:253–67 e255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28810147</ArticleId>
            <ArticleId IdType="pmc">5568814</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.07.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest. 2019;129:1278–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30628894</ArticleId>
            <ArticleId IdType="pmc">6391090</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI97642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829–42 e813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27745970</ArticleId>
            <ArticleId IdType="pmc">27745970</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2016.09.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128:1708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29608143</ArticleId>
            <ArticleId IdType="pmc">5873851</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI120803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22:729–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30962630</ArticleId>
            <ArticleId IdType="pmc">8052632</ArticleId>
            <ArticleId IdType="doi">10.1038/s41593-019-0370-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui X, Morales RT, Qian W, Wang H, Gagner JP, Dolgalev I, et al. Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials. 2018;161:164–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29421553</ArticleId>
            <ArticleId IdType="pmc">8059366</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2018.01.053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Zhang L, Zhang IY, Liang J, Wang H, Ouyang M, et al. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res. 2014;74:7285–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25326491</ArticleId>
            <ArticleId IdType="pmc">4268204</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-1240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterberg N, Ferrara N, Vacher J, Gaedicke S, Niedermann G, Weyerbrock A, et al. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Neuro Oncol. 2016;18:939–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26951383</ArticleId>
            <ArticleId IdType="pmc">4896547</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/now005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandenburg S, Muller A, Turkowski K, Radev YT, Rot S, Schmidt C, et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathologica. 2016;131:365–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26718201</ArticleId>
            <ArticleId IdType="doi">10.1007/s00401-015-1529-6</ArticleId>
            <ArticleId IdType="pmc">26718201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y, Zhu W, et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab. 2008;28:90–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17519976</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.jcbfm.9600509</ArticleId>
            <ArticleId IdType="pmc">17519976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiller KL, Anfang RR, Spiller KJ, Ng J, Nakazawa KR, Daulton JW, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials. 2014;35:4477–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24589361</ArticleId>
            <ArticleId IdType="pmc">24589361</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2014.02.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu C, Chrifi I, Mustafa D, van der Weiden M, Leenen PJM, Duncker DJ, et al. CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. Oncogene. 2017;36:5356–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28534507</ArticleId>
            <ArticleId IdType="pmc">5611481</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2017.145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4:226–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19265662</ArticleId>
            <ArticleId IdType="pmc">3688060</ArticleId>
            <ArticleId IdType="doi">10.1016/j.stem.2009.01.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J, Zhao Q, Wang J, Tian X, Wang J, Xia X, et al. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Lett. 2021;506:83–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33676940</ArticleId>
            <ArticleId IdType="doi">10.1016/j.canlet.2021.02.021</ArticleId>
            <ArticleId IdType="pmc">33676940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells. 2016;34:2026–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27145382</ArticleId>
            <ArticleId IdType="pmc">5820763</ArticleId>
            <ArticleId IdType="doi">10.1002/stem.2393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin J, Kim SS, Choi E, Oh YT, Lin W, Kim TH, et al. ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat Commun. 2020;11:2978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32532977</ArticleId>
            <ArticleId IdType="pmc">7293269</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-020-16789-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao W, Chu C, Zhou W, Huang Z, Zhai K, Fang X, et al. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. Nat Commun. 2020;11:3015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32541784</ArticleId>
            <ArticleId IdType="pmc">7295765</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-020-16827-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8:15080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28569747</ArticleId>
            <ArticleId IdType="pmc">5461490</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms15080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Xu J, Chen Z, Wang H, Xue H, Yang C, et al. Transfer of microrna via macrophage-derived extracellular vesicles promotes proneural-to-mesenchymal transition in glioma stem cells. Cancer Immunol Res. 2020;8:966–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32350000</ArticleId>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-19-0759</ArticleId>
            <ArticleId IdType="pmc">32350000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28052991</ArticleId>
            <ArticleId IdType="pmc">5426480</ArticleId>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19109155</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.240</ArticleId>
            <ArticleId IdType="pmc">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugolini A, Tyurin VA, Tyurina YY, Tcyganov EN, Donthireddy L, Kagan VE, et al. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. 2020;5:e138581.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16424049</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-1299</ArticleId>
            <ArticleId IdType="pmc">16424049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:35–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19572148</ArticleId>
            <ArticleId IdType="doi">10.1007/s00432-009-0634-0</ArticleId>
            <ArticleId IdType="pmc">19572148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134:2853–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24259296</ArticleId>
            <ArticleId IdType="doi">10.1002/ijc.28622</ArticleId>
            <ArticleId IdType="pmc">24259296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, et al. Induction of immunosuppressive functions and NF-kappaB by FLIP in monocytes. Nat Commun. 2018;9:5193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30518925</ArticleId>
            <ArticleId IdType="pmc">6281604</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-07654-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27381735</ArticleId>
            <ArticleId IdType="pmc">4935811</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms12150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc Natl Acad Sci USA. 2019;116:23714–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31712430</ArticleId>
            <ArticleId IdType="pmc">6876152</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1906346116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3:e122264.</Citation>
        </Reference>
        <Reference>
          <Citation>Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, et al. Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer Disco. 2020;10:1210–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-1355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SA, Ter Laan M, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro Oncol. 2016;18:1253–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27006175</ArticleId>
            <ArticleId IdType="pmc">4998996</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/now034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122:293–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25579983</ArticleId>
            <ArticleId IdType="doi">10.1007/s11060-015-1720-6</ArticleId>
            <ArticleId IdType="pmc">25579983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13:591–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21636707</ArticleId>
            <ArticleId IdType="pmc">3107102</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nor042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubinski D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, et al. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2016;18:807–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26578623</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nov280</ArticleId>
            <ArticleId IdType="pmc">26578623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chae M, Peterson TE, Balgeman A, Chen S, Zhang L, Renner DN, et al. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol. 2015;17:978–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25537019</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nou343</ArticleId>
            <ArticleId IdType="pmc">25537019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soderberg SS, Karlsson G, Karlsson S. Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N. Y Acad Sci. 2009;1176:55–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19796233</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2009.04569.x</ArticleId>
            <ArticleId IdType="pmc">19796233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38:541–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23477736</ArticleId>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.02.007</ArticleId>
            <ArticleId IdType="pmc">23477736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bah I, Kumbhare A, Nguyen L, McCall CE, El Gazzar M. IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development. Cell Immunol. 2018;332:32–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30025864</ArticleId>
            <ArticleId IdType="pmc">6129403</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cellimm.2018.07.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20:4096–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24907113</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0635</ArticleId>
            <ArticleId IdType="pmc">24907113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattila S, Tuominen H, Koivukangas J, Stenback F. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Neuropathology. 2009;29:156–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19347995</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1440-1789.2008.00963.x</ArticleId>
            <ArticleId IdType="pmc">19347995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, et al. Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013;2013:979748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23864770</ArticleId>
            <ArticleId IdType="pmc">3707225</ArticleId>
            <ArticleId IdType="doi">10.1155/2013/979748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T Cells and myeloid-derived suppressor cells. Cancer Res. 2016;76:5671–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27530322</ArticleId>
            <ArticleId IdType="pmc">5050119</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22:3924–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26957562</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2463</ArticleId>
            <ArticleId IdType="pmc">26957562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Qiu W, Liu Q, Qian M, Wang S, Zhang Z, et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. Oncogene. 2018;37:4239–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29713056</ArticleId>
            <ArticleId IdType="doi">10.1038/s41388-018-0261-9</ArticleId>
            <ArticleId IdType="pmc">29713056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alban TJ, Bayik D, Otvos B, Rabljenovic A, Leng L, Jia-Shiun L, et al. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Front Immunol. 2020;11:1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32625208</ArticleId>
            <ArticleId IdType="pmc">7315581</ArticleId>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, et al. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. 2021;7:eabc2511.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15313928</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-0465</ArticleId>
            <ArticleId IdType="pmc">15313928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, et al. Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol Res. 2019;7:1928–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31530559</ArticleId>
            <ArticleId IdType="pmc">6891201</ArticleId>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-19-0240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011;46:156–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20822377</ArticleId>
            <ArticleId IdType="doi">10.3109/00365521.2010.516450</ArticleId>
            <ArticleId IdType="pmc">20822377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17617589</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.179.2.977</ArticleId>
            <ArticleId IdType="pmc">17617589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wildes TJ, Grippin A, Dyson KA, Wummer BM, Damiani DJ, Abraham RS, et al. Cross-talk between T Cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma. Clin Cancer Res. 2018;24:3955–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29712687</ArticleId>
            <ArticleId IdType="pmc">6095818</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-3061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries IJ. Tumoricidal activity of human dendritic cells. Trends Immunol. 2014;35:38–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24262387</ArticleId>
            <ArticleId IdType="doi">10.1016/j.it.2013.10.007</ArticleId>
            <ArticleId IdType="pmc">24262387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, et al. Dendritic cell-based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma. J Immunol. 2015;195:367–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26026061</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.1401607</ArticleId>
            <ArticleId IdType="pmc">26026061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. 2016;7:13720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28008905</ArticleId>
            <ArticleId IdType="pmc">5196231</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms13720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12932356</ArticleId>
            <ArticleId IdType="doi">10.1016/S1074-7613(03)00208-5</ArticleId>
            <ArticleId IdType="pmc">12932356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol. 2004;75:504–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14742635</ArticleId>
            <ArticleId IdType="doi">10.1189/jlb.0603291</ArticleId>
            <ArticleId IdType="pmc">14742635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aspord C, Leccia MT, Charles J, Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res. 2013;1:402–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24778133</ArticleId>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0114-T</ArticleId>
            <ArticleId IdType="pmc">24778133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011;12:870–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18:6110–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22932670</ArticleId>
            <ArticleId IdType="pmc">3500434</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-2130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gousias K, von Ruecker A, Voulgari P, Simon M. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas. J Neuroimmunol. 2013;264:84–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24071056</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.09.001</ArticleId>
            <ArticleId IdType="pmc">24071056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Acker HH, Anguille S, De Reu H, Berneman ZN, Smits EL, Van Tendeloo VF. Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta T cell functions through IL-15 secretion. Front Immunol. 2018;9:658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29692776</ArticleId>
            <ArticleId IdType="pmc">5902500</ArticleId>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamran N, Chandran M, Lowenstein PR, Castro MG. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clin Immunol. 2018;189:34–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27777083</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clim.2016.10.008</ArticleId>
            <ArticleId IdType="pmc">27777083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chabot V, Martin L, Meley D, Sensebe L, Baron C, Lebranchu Y, et al. Unexpected impairment of TNF-alpha-induced maturation of human dendritic cells in vitro by IL-4. J Transl Med. 2016;14:93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27080531</ArticleId>
            <ArticleId IdType="pmc">4832484</ArticleId>
            <ArticleId IdType="doi">10.1186/s12967-016-0848-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol. 2004;173:4352–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15383564</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.173.7.4352</ArticleId>
            <ArticleId IdType="pmc">15383564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, et al. Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat Commun. 2019;10:862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30770835</ArticleId>
            <ArticleId IdType="pmc">6377651</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-019-08770-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Liu P, Xin S, Wang Z, Li J. Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells. Exp Cell Res. 2017;360:66–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28782555</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2017.07.031</ArticleId>
            <ArticleId IdType="pmc">28782555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29843811</ArticleId>
            <ArticleId IdType="pmc">5975654</ArticleId>
            <ArticleId IdType="doi">10.1186/s12967-018-1507-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019;25:5799–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31320597</ArticleId>
            <ArticleId IdType="pmc">8132111</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-0261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, et al. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res. 2020;26:4983–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32605912</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-4092</ArticleId>
            <ArticleId IdType="pmc">32605912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell DR, Huttenlocher A. Neutrophils in the tumor microenvironment. Trends Immunol. 2016;37:41–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26700397</ArticleId>
            <ArticleId IdType="doi">10.1016/j.it.2015.11.008</ArticleId>
            <ArticleId IdType="pmc">26700397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song L, Zhang S, Duan C, Ma S, Hussain S, Wei L, et al. Genome-wide identification of lncRNAs as novel prognosis biomarkers of glioma. J Cell Biochem. 2019;120:19518–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31297871</ArticleId>
            <ArticleId IdType="doi">10.1002/jcb.29259</ArticleId>
            <ArticleId IdType="pmc">31297871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1:e85841.</Citation>
        </Reference>
        <Reference>
          <Citation>Chio CC, Wang YS, Chen YL, Lin SJ, Yang BC. Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice. Br J Cancer. 2001;85:1185–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11710833</ArticleId>
            <ArticleId IdType="pmc">2375147</ArticleId>
            <ArticleId IdType="doi">10.1054/bjoc.2001.2055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013;114:149–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23780645</ArticleId>
            <ArticleId IdType="doi">10.1007/s11060-013-1164-9</ArticleId>
            <ArticleId IdType="pmc">23780645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar BA, et al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neurooncol. 2017;132:463–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28332000</ArticleId>
            <ArticleId IdType="doi">10.1007/s11060-017-2395-y</ArticleId>
            <ArticleId IdType="pmc">28332000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massara M, Persico P, Bonavita O, Mollica Poeta V, Locati M, Simonelli M, et al. Neutrophils in gliomas. Front Immunol. 2017;8:1349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29123517</ArticleId>
            <ArticleId IdType="pmc">5662581</ArticleId>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schernberg A, Nivet A, Dhermain F, Ammari S, Escande A, Pallud J, et al. Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clin Transl Radiat Oncol. 2018;10:47–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29928705</ArticleId>
            <ArticleId IdType="pmc">6008628</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ctro.2018.04.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, et al. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun. 2017;5:39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28532485</ArticleId>
            <ArticleId IdType="pmc">5439117</ArticleId>
            <ArticleId IdType="doi">10.1186/s40478-017-0443-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, et al. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20:187–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24240114</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-1279</ArticleId>
            <ArticleId IdType="pmc">24240114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15:96–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25614008</ArticleId>
            <ArticleId IdType="pmc">4369764</ArticleId>
            <ArticleId IdType="doi">10.1038/nrc3893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters BK, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011;17:6992–7002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21948231</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1107</ArticleId>
            <ArticleId IdType="pmc">21948231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33110073</ArticleId>
            <ArticleId IdType="pmc">7591536</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-020-19193-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manda-Handzlik A, Demkow U The Brain entangled: the contribution of neutrophil extracellular traps to the diseases of the central nervous system. Cells. 2019;8:1477.</Citation>
        </Reference>
        <Reference>
          <Citation>Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001;189:197–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11598905</ArticleId>
            <ArticleId IdType="doi">10.1002/jcp.10014</ArticleId>
            <ArticleId IdType="pmc">11598905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23:141–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23485549</ArticleId>
            <ArticleId IdType="doi">10.1016/j.semcancer.2013.02.005</ArticleId>
            <ArticleId IdType="pmc">23485549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangere V, Vincent J, et al. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget. 2016;7:70948–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27487142</ArticleId>
            <ArticleId IdType="pmc">5342600</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.10898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrover JM, Nicolas-Avila JA, Hidalgo A. Aging: a temporal dimension for neutrophils. Trends Immunol. 2016;37:334–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27083489</ArticleId>
            <ArticleId IdType="doi">10.1016/j.it.2016.03.005</ArticleId>
            <ArticleId IdType="pmc">27083489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Chen G, Manwani D, Mortha A, Xu C, Faith JJ, et al. Neutrophil ageing is regulated by the microbiome. Nature. 2015;525:528–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26374999</ArticleId>
            <ArticleId IdType="pmc">4712631</ArticleId>
            <ArticleId IdType="doi">10.1038/nature15367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1:aaf8943.</Citation>
        </Reference>
        <Reference>
          <Citation>Chai E, Zhang L, Li C. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression. Cancer Manag Res. 2019;11:7307–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31447588</ArticleId>
            <ArticleId IdType="pmc">6683959</ArticleId>
            <ArticleId IdType="doi">10.2147/CMAR.S210545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZL, Zhang CB, Liu YQ, Wang Z, Jiang T. Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. CNS Neurosci Ther. 2019;25:876–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30912613</ArticleId>
            <ArticleId IdType="pmc">6630006</ArticleId>
            <ArticleId IdType="doi">10.1111/cns.13120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehrer S, Rheinstein PH, Rosenzweig KE. Allergy may confer better survival on patients with gliomas. Clin Neurol Neurosurg. 2019;177:63–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30611004</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clineuro.2018.12.021</ArticleId>
            <ArticleId IdType="pmc">30611004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy A, Coum A, Marinescu VD, Polajeva J, Smits A, Nelander S, et al. Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells. Oncotarget. 2015;6:23647–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26164207</ArticleId>
            <ArticleId IdType="pmc">4695142</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.4640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polajeva J, Sjosten AM, Lager N, Kastemar M, Waern I, Alafuzoff I, et al. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PloS One. 2011;6:e25222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21949886</ArticleId>
            <ArticleId IdType="pmc">3176317</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0025222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS, et al. Macrophage exclusion after radiation therapy (MERT): a first in human phase I/II trial using a CXCR4 inhibitor in glioblastoma. Clin Cancer Res. 2019;25:6948–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31537527</ArticleId>
            <ArticleId IdType="pmc">6891194</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, et al. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014;21:38–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24434573</ArticleId>
            <ArticleId IdType="pmc">4035218</ArticleId>
            <ArticleId IdType="doi">10.1038/cgt.2013.81</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribechini E, Hutchinson JA, Hergovits S, Heuer M, Lucas J, Schleicher U, et al. Novel GM-CSF signals via IFN-gammaR/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Adv. 2017;1:947–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29296736</ArticleId>
            <ArticleId IdType="pmc">5737598</ArticleId>
            <ArticleId IdType="doi">10.1182/bloodadvances.2017006858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, et al. MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018;20:92–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28605477</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nox111</ArticleId>
            <ArticleId IdType="pmc">28605477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poli A, Wang J, Domingues O, Planaguma J, Yan T, Rygh CB, et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget. 2013;4:1527–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24127551</ArticleId>
            <ArticleId IdType="pmc">3824525</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.1291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase II study. Neuro Oncol. 2016;18:557–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26449250</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nov245</ArticleId>
            <ArticleId IdType="pmc">26449250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Rajappa P, Hu W, Hoffman C, Cisse B, Kim JH, et al. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest. 2017;127:1826–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28394259</ArticleId>
            <ArticleId IdType="pmc">5409793</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI86443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013;15:1079–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23828240</ArticleId>
            <ArticleId IdType="pmc">3714160</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/not082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2016;8:39–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26666269</ArticleId>
            <ArticleId IdType="doi">10.15252/emmm.201505505</ArticleId>
            <ArticleId IdType="pmc">26666269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA. 2016;113:4476–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27044098</ArticleId>
            <ArticleId IdType="pmc">4843473</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1525360113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, et al. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017;36:3749–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28218903</ArticleId>
            <ArticleId IdType="pmc">5491354</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2017.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Ross JL, Hambardzumyan D. Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages. Proc Natl Acad Sci USA. 2019;116:14254–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31235603</ArticleId>
            <ArticleId IdType="pmc">6628659</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1902366116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho HR, Kumari N, Thi Vu H, Kim H, Park CK, Choi SH. Increased antiangiogenic effect by blocking CCL2-dependent macrophages in a rodent glioblastoma model: correlation study with dynamic susceptibility contrast perfusion MRI. Sci Rep. 2019;9:11085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31366997</ArticleId>
            <ArticleId IdType="pmc">6668454</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-019-47438-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Res. 2018;78:718–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29118089</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0599</ArticleId>
            <ArticleId IdType="pmc">29118089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4246418</ArticleId>
            <ArticleId IdType="pmc">4246418</ArticleId>
            <ArticleId IdType="doi">10.1038/nature13954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25765070</ArticleId>
            <ArticleId IdType="pmc">4993154</ArticleId>
            <ArticleId IdType="doi">10.1126/science.aaa1348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Nunez NG, et al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 2020;11:931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32071302</ArticleId>
            <ArticleId IdType="pmc">7028933</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-020-14642-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peereboom DM, Alban TJ, Grabowski MM, Alvarado AG, Otvos B, Bayik D, et al. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 2019;4:e130748.</Citation>
        </Reference>
        <Reference>
          <Citation>Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, et al. Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther. 2017;25:232–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28129117</ArticleId>
            <ArticleId IdType="pmc">5363306</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ymthe.2016.10.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000;9:e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16817691</ArticleId>
            <ArticleId IdType="doi">10.3171/foc.2000.9.6.9</ArticleId>
            <ArticleId IdType="pmc">16817691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoges S, Tejada S, de Cerio AL, Gallego Perez-Larraya J, Espinos J, Idoate MA, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28499389</ArticleId>
            <ArticleId IdType="pmc">5427614</ArticleId>
            <ArticleId IdType="doi">10.1186/s12967-017-1202-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res. 2017;23:1898–909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28411277</ArticleId>
            <ArticleId IdType="pmc">5559300</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, et al. Dendritic cells enhance polyfunctionality of adoptively transferred t cells that target cytomegalovirus in glioblastoma. Cancer Res. 2018;78:256–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29093005</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0469</ArticleId>
            <ArticleId IdType="pmc">29093005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galani V, Papadatos SS, Alexiou G, Galani A, Kyritsis AP. In vitro and in vivo preclinical effects of type I IFNs on gliomas. J Interferon Cytokine Res. 2017;37:139–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28387596</ArticleId>
            <ArticleId IdType="doi">10.1089/jir.2016.0094</ArticleId>
            <ArticleId IdType="pmc">28387596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12:692–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28650441</ArticleId>
            <ArticleId IdType="doi">10.1038/nnano.2017.54</ArticleId>
            <ArticleId IdType="pmc">28650441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Zhang H, Tie C, Yan C, Deng Z, Wan Q, et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat Commun. 2018;9:4777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30429468</ArticleId>
            <ArticleId IdType="pmc">6235838</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-07250-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chonan M, Saito R, Shoji T, Shibahara I, Kanamori M, Sonoda Y, et al. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models. Neuro Oncol. 2015;17:1453–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26008605</ArticleId>
            <ArticleId IdType="pmc">4648302</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nov090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoji T, Saito R, Chonan M, Shibahara I, Sato A, Kanamori M, et al. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro Oncol. 2016;18:1120–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26917236</ArticleId>
            <ArticleId IdType="pmc">4933484</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/now023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25762141</ArticleId>
            <ArticleId IdType="pmc">4510871</ArticleId>
            <ArticleId IdType="doi">10.1038/nature14320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8:1736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29170400</ArticleId>
            <ArticleId IdType="pmc">5701019</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-017-01566-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity. 2006;25:441–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2006.07.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25:455–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2006.07.011</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
